Boehringer Ingelheim has reported new phase 3 data showing its dual glucagon/GLP‑1 agonist survodutide achieved weight loss of up to 13.1% in adults with obesity and type 2 diabetes.
The SYNCHRONIZE‑2 trial met both co‑primary endpoints, with placebo‑adjusted weight loss of 3.1% after 76 weeks. Up to 79.3% of participants achieved at least 5% weight reduction.
The study also showed improvements in key cardiometabolic markers. Participants recorded HbA1c reductions of up to 1.21% from a baseline of 7.4%, compared with 0.03% on placebo. Waist circumference fell by 11.1 cm versus 3.5 cm on placebo.
Dr Sean Wharton, Coordinating Investigator, said: “Obesity and type 2 diabetes are deeply intertwined, with excess weight increasing the risk of T2D. For people living with these conditions, sustained weight loss is often a biological struggle rather than a lack of willpower.” He added: “Seeing improvements in glycemic control and insulin sensitivity alongside weight loss provides evidence that tackling obesity can positively influence broader metabolic health.”
Survodutide is designed to improve glycemic control, reduce appetite and support reductions in liver fat. Boehringer said the balance of dual agonism may help preserve glucose management despite glucagon’s traditional association with raising blood sugar. The therapy remains investigational and is not approved.
Shashank Deshpande, Head of Human Pharma at Boehringer Ingelheim, explained: “The SYNCHRONIZE‑2 results demonstrate meaningful weight loss alongside improvements in glycemic control and other key markers of metabolic health, reinforcing our belief that obesity should be addressed as a complex chronic disease with interconnected health consequences.” He continued: “We remain committed to advancing innovative treatment approaches that address the diverse needs of people living with obesity across different stages of disease and risk profiles.”
Gastrointestinal events were the most common adverse effects, typically mild to moderate, with discontinuations more frequent during dose escalation. Upcoming trials will use more flexible titration strategies.
A body composition sub study from SYNCHRONIZE‑1 showed preferential reductions in visceral and liver fat, with muscle accounting for no more than 10% of total tissue lost. Boehringer expects further data later this year, including results from its cardiovascular outcomes trial.
